Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.60 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.60 |
| ▸ | GNPAT | O15228 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.55 |
| ▸ | CHRNG | P07510 | 1/20 | 0.55 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.55 |
| ▸ | CHRND | Q07001 | 1/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30712028 | 1.00 | ERAP2 (0.60) | ERAP2LNPEPGNPATOPRK1CHRNA1 | |
| SCHEMBL30523241 | 1.00 | ERAP2 (0.60) | ERAP2LNPEPGNPATOPRK1CHRNA1 | |
| SCHEMBL31347785 | 1.00 | ERAP2 (0.60) | ERAP2LNPEPGNPATOPRK1CHRNA1 | |
| SCHEMBL31474739 | 1.00 | ERAP2 (0.60) | ERAP2LNPEPGNPATOPRK1CHRNA1 | |
| SCHEMBL29462359 | 1.00 | ERAP2 (0.60) | ERAP2LNPEPGNPATOPRK1CHRNA1 | |
| SCHEMBL29641060 | 0.97 | NPY1R (0.58) | ERAP2LNPEPGNPATOPRK1CHRNA1 | |
| SCHEMBL30523264 | 0.97 | LNPEP (0.63) | ERAP2LNPEPGNPATOPRK1CHRNA1 | |
| SCHEMBL29577087 | 0.96 | NPY4R (0.59) | ERAP2LNPEPGNPATCHRNA1CHRNG | |
| SCHEMBL29576811 | 0.96 | NPY4R (0.59) | ERAP2LNPEPGNPATCHRNA1CHRNG | |
| SCHEMBL30931517 | 0.95 | LNPEP (0.62) | ERAP2LNPEPGNPATOPRK1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302163-A1 | RADIOPHARMACEUTICAL AND METHODS | POINT BIOPHARMA INC (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302163-A1 | RADIOPHARMACEUTICAL AND METHODS | FOLH1, PSMA2, PSMA7 | ERAP2 182/4885LNPEP 15/4885GNPAT 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.